地塞米松对晚期非小细胞肺癌化疗患者的临床效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of dexamethasone on chemotherapy in patients with advanced non-small cell lung cancer(NSCLC).Methods Eighty patients with advanced NSCLC admitted into our hospital from January to December in 2016 were enrolled and randomly divided into two groups.40 cases of the control group was used with chemothrapy,while 40 cases of the research group was added with dexamethasone.The therapeutic effect was compared in both groups.Results There was no statistically significant difference in short-term effective rate between the two groups(P＞0.05).Before therapy,the levels of HIF-1α and VEGF had no statistically significant difference (P＞0.05).After treatment,they were both improved,and the levels in the research group were much lower compared with those in the control group (P＜0.05).Before treatment,the immune function in the two groups had no statistically significant difference(P＞0.05).After treatment,they were both improved,and improvement in the research group was superior to that in the control group (P＜0.05).Conclusion For patients with advanced NSCLC,combination of dexamethasone is beneficial to improve patients′immune function,which should be recommended for clinical application.

Key words： Dexamethasone Advanced non-small cell lung cancer Chemotherapy Effective rate Immune function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Zuo-chao
	LIU Yi
	ZENG Chun-sheng
	KANG Zhao-xun
	LI Zhao-yan
	WANG Ju-ping

Cite this article:

HUANG Zuo-chao,LIU Yi,ZENG Chun-sheng, et al. Clinical effect of dexamethasone on chemotherapy in patients with advanced non-small cell lung cancer[J]. 中国当代医药, 2017, 24(28): 147-149.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I28/147

[1]	唐丹.晚期非小细胞肺癌化疗疗效的临床观察[J].四川医学，2015，36（10）：1446-1448.
[2]	金龙，曹玉华，黄带发，等.高龄晚期非小细胞肺癌患者化疗疗效及安全性[J].临床军医杂志，2015，2（6）：592-595.
[3]	Checinsk a A，Hoogeland BSJ，Rodriguez JA，et al.Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells[J].ECR，2016，313 （6）：1215-1224.
[4]	马楠，马东初，丁震宇，等.化疗联合DC-CIK治疗老年晚期非小细胞肺癌的疗效评价[J].解放军医药杂志，2015，3（1）：37-40.
[5]	黄鲁众，张晓晔，刘艳，等.阿瑞匹坦联合5-HT3受体拮抗剂和地塞米松预防化疗相关性恶心和呕吐的Meta分析[J].现代肿瘤医学，2015，1（15）：2198-2203.
[6]	Schuler M，Yang JC，Park K，et al.Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy，erlotinib/gefitinib and afatinib：phase Ⅲ randomized LUX-Lung 5 trial.[J].AOO，2016，27（3）：417-423.
[7]	李开春，王静文，施展，等.阿瑞匹坦联合昂丹司琼和地塞米松预防化疗诱发恶心和呕吐的疗效及安全性[J].国际肿瘤学杂志，2016，43（8）：561-564.
[8]	王文娜，林秋菊，罗健.雷贝拉唑联合托烷司琼及地塞米松防治肿瘤患者化疗所致胃肠道反应的疗效研究 [J].中国全科医学，2015，1（22）：2688-2691.
[9]	Kazandjian D，Suzman DL，Blumenthal G，et al.FDA approval summary：Nivolumab for the treatment of metastatic nonsmall cell lung cancer with progression on or after platinum-based chemotherapy[J].Oncologist，2016，21（5）：634-642.
[10]	闫桂军，赵作银，王培振，等.小剂量地塞米松预处理在TP 方案化疗中的应用[J].齐鲁医学杂志，2015，3（5）：543-544.
[11]	赵华，贾咏梅.DC-CIK免疫治疗联合常规化疗对非小细胞肺癌患者血清学及外周血免疫功能指标的影响[J].海南医学院学报，2015，21（7）：967-970.
[12]	高丽，陈丹.晚期非小细胞肺癌疗效监测的研究进展[J].肿瘤研究与临床，2016，28（11）：777-781.
[13]	康红刚，张静，王宝中，等.DC-CIK联合放化疗对小细胞肺癌患者免疫功能的影响[J].癌症进展，2016，14（5）：461-463.
[14]	陆莎，孙盈，陈召，等.不同化疗方案联合手术治疗非小细胞肺癌的临床疗效及对患者免疫功能的影响分析[J].现代生物医学进展，2016，16（30）：5882-5885.
[15]	石安辉，朱广迎.局部晚期非小细胞肺癌放化疗的现状与进展[J].临床外科杂志，2016，24（7）：505-508.
[16]	赵铎，高宝安.中晚期非小细胞肺癌联合治疗研究进展[J].海南医学，2016，27（3）：438-441.